Enhanced patient selection for Clinical Trials

The selection of the right patients for clinical trials is a challenge. MutantDx is well positioned to take advantage of this unfilled need by virtue of our unmatched ability to not only detect, but also verify DNA cancer mutations at extraordinarily low concentrations (femtograms).

Such enhanced patient selection results in two significant advantages:

  • lower trial costs, and
  • faster track for FDA approval, as better patient selection will result in a higher percentage of positive responses to any new targeted chemotherapy.

Furthermore, re-testing tumor samples from failed clinical trials that lacked patient selection will likely result in some rejected drugs (orphan drugs) finding new approved applications given the advantages of MutantDx technologies.

Dr Roger Hodkinson


MutantDx Inc.

17204 106A Avenue
Edmonton, Alberta
Canada T5S 1E6